Navigation Links
New data from 10-year global flea monitoring program confirms imidacloprid remains highly effective
Date:8/13/2009

SHAWNEE, Kan, 08/13/2009 Bayer Animal Heath announced today at the 22nd World Association for the Advancement of Veterinary Parasitology (WAAVP), Calgary, Canada the latest results of a large-scale, international, independent Flea Susceptibility Monitoring (FSM) program, demonstrating that imidacloprid remains highly effective for the control of fleas in companion animals.

The data show that fleas collected from around the globe continue to be as highly susceptible to imidacloprid today as they were when the monitoring commenced. In 2009, the FSM program celebrates its 10th year. Since 2001, when the diagnostic dose was established enabling field monitoring to begin, 1356 samples have been submitted, 1014 samples have been analyzed and 13 flea isolates identified for more detailed laboratory investigation. After additional testing none of those isolates were considered to have reduced susceptibility. The ongoing monitoring through the innovative FSM program confirms that veterinarians and pet owners can continue to trust in imidacloprid, the active ingredient in Bayer Animal Health's Advantage Topical Solution and K9 Advantix.

The Bayer Animal Health-funded FSM program is the first and only initiative of its kind in the field of companion animal parasites and includes a group of internationally renowned, independent researchers who work together with Bayer Animal Health to continuously monitor the susceptibility of fleas to imidacloprid. Under the international program, data is collected from the United States, Germany, France and the UK. In the US alone, there are over 100 clinics across 23 states involved in the collection of field isolates which are then sent to independent laboratories in California and Alabama for testing.

"The inception in 1999 of the global monitoring program for susceptibility of fleas to imidacloprid was a significant milestone in resistance surveillance and risk assessment. That this program has now reached its tenth anniversary testifies to the strength and motivation of the international team conducting the research, and the commitment of Bayer to ensure that its products continue to provide proven, efficient, reliable flea control", said Dr. Michael Rust, Professor of Entomology, College of Natural and Agricultural Sciences, University of California, Riverside.

The methodology utilized by the FSM follows a three-step approach. Flea egg samples are collected by participating veterinarians from infested animals and sent to the monitoring laboratories for testing. Twenty eggs are reared on media containing 3 ppm imidacloprid (the diagnostic dose) and 20 in media without imidacloprid (controls). Adult emergence is measured and if >5%, that population of fleas is maintained to allow further laboratory evaluation of susceptibility. The third evaluation step is to investigate the susceptibility of the flea population when placed on dogs and treated with Advantage. To date, no isolates have survived the second stage of the testing process, proving the long-standing efficacy of imidacloprid in killing fleas.

"Ten years after the initiation of the Flea Susceptibility Monitoring program, our efforts remain a unique and important strategy for assessing the continuing efficacy of imidacloprid against fleas. Monitoring the performance of current agents like imidacloprid is necessary to help maintain a longer, viable product life for these products", said Dr. Bryon Blagburn, Distinguished University Professor, College of Veterinary Medicine, Auburn University, USA.

"Bayer Animal Health is committed to remaining at the forefront of understanding parasitology and its related diseases, and, in this way, providing effective treatments that continue to ensure optimal animal health," said Sarah Weston, Global Veterinary Services Manager, Bayer Animal Health.


'/>"/>

Contact: Bob Walker
bob.walker.b@bayer.com
913-268-2577
Weber Shandwick Worldwide
Source:Eurekalert

Related medicine news :

1. VA Launches 10-Year Health Study of 60,000 New Veterans
2. First 10-year follow-up shows that treatment with AVONEX leads to long-term benefits in early multiple sclerosis patients
3. Thermogenesis Technology Products Surpass Processing of More Than One Million Units of Cord Blood Stem Cells at 10-Year Milestone
4. Hand Transplantation Marks Historical 10-Year Milestone
5. Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk
6. 5- and 10-year survival continues to improve for US children with hematologic malignancies
7. Stereotaxis Magnetic Navigation System Used to Successfully Treat an Inoperable Congenital Heart Defect in a 10-Year Old Patient
8. ClearWay Minnesota(SM) Celebrates 10-Year Anniversary of Settlement
9. Sonic Innovations Launches Two New Hearing Aid Products in Conjunction With Companys 10-Year Anniversary
10. Sonic Innovations Celebrates 10-Year Anniversary
11. Childrens Healthcare of Atlanta Announces Major Investment in Pediatric Research as Part of 10-Year Vision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... The Florida Hospital Tampa Wound Healing ... Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute ... and facilities have earned this distinction. This is the second time the Florida ...
(Date:12/8/2016)... JENNERSVILLE, Pa. (PRWEB) , ... December 08, 2016 ... ... Penn Medicine Southern Chester County, a Property owned by an affiliate of Seavest, ... 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman ... law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at ... DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology Group ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development solutions for drugs, biologics and consumer health products, today announced that it ... up in 2006 as a non-profit organization to unite pharmaceutical and healthcare companies ...
(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company ... severe, rare diseases, today announced that senior management will participate in ... Conference at the InterContinental Barclay Hotel in New York ... ET. About aTyr Pharma ... aTyr Pharma is engaged in the ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, Inc. ... (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to ... for the treatment of bacterial infections including those ... recognized as an attractive antibacterial target for more ... of suitable chemical starting points has hampered its ...
(Date:12/8/2016)... -- The global biosurgery market is expected to grow at ... 2016 to 2021. The market is poised to reach ... in 2016. The market is primarily driven by rising ... and spinal problems, increasing clearance of biosurgery products by ... management. In this report, the biosurgery market ...
Breaking Medicine Technology: